Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Earnings Season Inevitabilities

Executive Summary

Johnson & Johnson, Actelion and Roche launched the 2016 third-quarter earnings season with a somewhat mixed opening salvo. The harsh investor response probably reflected an awareness of the inevitability of generic competition.

Advertisement

Related Content

Stockwatch: Awkward Developments Pricking J.P. Morgan Bubble
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Stockwatch: Third-Quarter Earnings Portents
Stockwatch: Earnings Season Appears Not At Home To Brexit
REMS “Abuses” Concern FDA, But Can Scolding Help Speed Generic Entry?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel